Literature DB >> 33194309

Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate Cancer.

Rhiannon McBean1, Anisa Kumari1, Louise McEwan1, James Walters1, David Wong1.   

Abstract

Staging/restaging of prostate cancer utilizing Gallium-68 (68Ga) prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in combination with an intravenous urogram allows improved discrimination between radiotracer activity in the renal tract and small pelvic nodes or local recurrences. Within this pictorial essay, we describe the imaging protocol utilized at our institution and present cases which demonstrate the utility of this combined imaging approach.
© 2020 Published by Scientific Scholar on behalf of Journal of Clinical Imaging Science.

Entities:  

Keywords:  Positron emission tomography; Prostate cancer imaging; Prostate cancer staging; Prostate-specific membrane antigen positron emission tomography/ computed tomography; Urogram

Year:  2020        PMID： 33194309      PMCID： PMC7656033          DOI： 10.25259/JCIS_88_2020

Source DB:  PubMed          Journal:  J Clin Imaging Sci        ISSN： 2156-5597


  8 in total

1.  Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer.

Authors:  Niall Fennessy; Jonathan Lee; Jane Shin; Bao Ho; Syed Aman Ali; Royce Paschkewitz; Louise Emmett
Journal:  J Med Imaging Radiat Oncol       Date:  2017-06-17       Impact factor: 1.735

2.  Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.

Authors:  Louise McEwan; Rhiannon McBean; John Yaxley; David Wong
Journal:  J Med Imaging Radiat Oncol       Date:  2019-03-06       Impact factor: 1.735

3.  68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging.

Authors:  Thorsten Derlin; Desiree Weiberg; Christoph von Klot; Hans-Jürgen Wester; Christoph Henkenberens; Tobias L Ross; Hans Christiansen; Axel S Merseburger; Frank M Bengel
Journal:  Eur Radiol       Date:  2016-03-24       Impact factor: 5.315

4.  Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.

Authors:  Levent Kabasakal; Emre Demirci; Meltem Ocak; Reşit Akyel; Jamal Nematyazar; Aslan Aygun; Metin Halac; Zubeyir Talat; Ahmet Araman
Journal:  Nucl Med Commun       Date:  2015-06       Impact factor: 1.690

5.  The use of 68  Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.

Authors:  Greta Meredith; David Wong; John Yaxley; Geoff Coughlin; Les Thompson; Boon Kua; Troy Gianduzzo
Journal:  BJU Int       Date:  2016-09-23       Impact factor: 5.588

Review 6.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Marlon Perera; Nathan Papa; Daniel Christidis; David Wetherell; Michael S Hofman; Declan G Murphy; Damien Bolton; Nathan Lawrentschuk
Journal:  Eur Urol       Date:  2016-06-28       Impact factor: 20.096

Review 7.  (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.

Authors:  Isabel Rauscher; Tobias Maurer; Wolfgang P Fendler; Wieland H Sommer; Markus Schwaiger; Matthias Eiber
Journal:  Cancer Imaging       Date:  2016-06-08       Impact factor: 3.909

8.  68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer.

Authors:  Amir Iravani; Michael S Hofman; Tony Mulcahy; Scott Williams; Declan Murphy; Bimal K Parameswaran; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2017-12-21       Impact factor: 3.909
  8 in total
  1 in total

1.  Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy.

Authors:  Matthew J Roberts; Andrew Morton; Nathan Papa; Anthony Franklin; Sheliyan Raveenthiran; William J Yaxley; Geoffrey Coughlin; Troy Gianduzzo; Boon Kua; Louise McEwan; David Wong; Brett Delahunt; Lars Egevad; Hemamali Samaratunga; Nicholas Brown; Robert Parkinson; Louise Emmett; John W Yaxley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-17       Impact factor: 10.057
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.